Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CF
Status:
Completed
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
"This is a randomised, double-blind, placebo-controlled multi-centre study to investigate
safety and tolerability and to provide pharmacokinetic and pharmacodynamics information of
orally inhaled multiple doses (80 mg, 160 mg or 320 mg) of the nebulised neutrophil elastase
inhibitor POL6014 in patients with Cystic Fibrosis. The controlled inhalation will occur via
the eFlow® nebuliser system (manufacturer: PARI Pharma GmbH, Germany)".